{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:18:55Z","timestamp":1786990735581,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ijid.2021.01.032","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T11:56:31Z","timestamp":1611143791000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia"],"prefix":"10.1016","volume":"104","author":[{"given":"Antoni","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Garrity-Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith N.","family":"Steenbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Eckburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita F.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Tzanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.01.032_bib0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ebiom.2017.09.023","article-title":"Lymphopenic community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality","volume":"24","author":"Bermejo-Martin","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijid.2021.01.032_bib0010","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.01.032_bib0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/jac\/dkh458","article-title":"Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe","volume":"54","author":"Bruinsma","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.01.032_bib0020","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","article-title":"Antimicrobial-resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications","volume":"24","author":"Cherazard","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.ijid.2021.01.032_bib0025","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/505871","article-title":"Macrolide resistance in bacteremic pneumococcal disease: implications for patient management","volume":"43","author":"Daneman","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.01.032_bib0030","series-title":"Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. EMA\/175398\/2019","author":"European Medicines Agency","year":"2019"},{"key":"10.1016\/j.ijid.2021.01.032_bib0035","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.ijid.2021.01.032_bib0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2021.01.032_bib0045","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3201\/eid1605.091424","article-title":"Increase in pneumococcus macrolide resistance","volume":"16","author":"Hicks","year":"2010","journal-title":"USA. Emerg Infect Dis"},{"key":"10.1016\/j.ijid.2021.01.032_bib0050","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/375078","article-title":"Fluoroquinolone-associated tendinopathy: a critical review of the literature","volume":"36","author":"Khaliq","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.01.032_bib0055","doi-asserted-by":"crossref","first-page":"e02368","DOI":"10.1128\/AAC.02368-16","article-title":"In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl","key":"10.1016\/j.ijid.2021.01.032_bib0060","first-page":"S10","article-title":"Hot topics in primary care: community-acquired bacterial pneumonia \u2013 is there anything new?","volume":"66","author":"Liu","year":"2017","journal-title":"J Fam Pract"},{"key":"10.1016\/j.ijid.2021.01.032_bib0065","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.01.032_bib0070","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2147\/COPD.S135338","article-title":"Ampicillin resistance in Haemophilus influenzae from COPD patients in the UK","volume":"12","author":"Maddi","year":"2017","journal-title":"Int J COPD"},{"key":"10.1016\/j.ijid.2021.01.032_bib0075","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/cid\/cis045","article-title":"Methicillin-resistant Staphylococcus aureus and community-acquired pneumonia: an evolving relationship","volume":"54","author":"Mandell","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.01.032_bib0080","first-page":"1260","article-title":"Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU","volume":"127","author":"Marrie","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2021.01.032_bib0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12931-018-0781-4","article-title":"Trends in mortality from pneumonia in the Europe union: a temporal analysis of the European detailed mortality database between 2001 and 2014","volume":"19","author":"Marshall","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.ijid.2021.01.032_bib0090","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2021.01.032_bib0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.ijid.2021.01.032_bib0100","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/AAC.00779-07","article-title":"Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia","volume":"52","author":"Morozumi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.01.032_bib0105","series-title":"Guideline NG138: Pneumonia (community-acquired): antimicrobial prescribing. London: NICE","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"10.1016\/j.ijid.2021.01.032_bib0110","doi-asserted-by":"crossref","first-page":"k678","DOI":"10.1136\/bmj.k678","article-title":"Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study","volume":"360","author":"Pasternak","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2021.01.032_bib0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17476348.2019.1562339","article-title":"The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance","volume":"13","author":"Peyrani","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.ijid.2021.01.032_bib0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00018-17","article-title":"Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010\u20132011","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2021.01.032_bib0125","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/ciz397","article-title":"Early clinical response in community-acquired bacterial pneumonia: from clinical endpoint to clinical practice","volume":"69","author":"Ramirez","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.01.032_bib0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.01.032_bib0135","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.01.032_bib0140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2021.01.032_bib0145","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.ijid.2021.01.032_bib0150","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ijid.2021.01.032_bib0155","series-title":"FDA Drug Safety Communications: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes","author":"US Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.ijid.2021.01.032_bib0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:59:43Z","timestamp":1761119983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":32,"alternative-id":["S1201971221000448"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.01.032","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}